There are currently 334 clinical trials in Norfolk, Virginia looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's Hospital of The King's Daughters, Sentara Norfolk General Hospital, Virginia Oncology Associates and Eastern Virginia Medical School. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
NCT05224102
Recruiting
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Wagner Kapoor Institute, Norfolk, Virginia
Conditions: Diabetic Macular Edema
Register for Updates
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
NCT05934487
Recruiting
This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: Randomized Arm - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class II HF patients. Treatment Arm (Cohort 1) Active Control Arm (Cohort 2) Crossover Arm (Cohort 3) Single Arm - To demonstrate safety an... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Sentara Healthcare, Norfolk, Virginia
Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III
Register for Updates
Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes
NCT06273891
Recruiting
The goal of this study is to help identify the best antibiotic treatment for pregnant people when their water breaks prematurely (a condition abbreviated as PPROM). Current practice is to attempt to maintain the pregnancy until at least 34 weeks gestational age, when the risks of prematurity to the baby are lessened. Research shows that antibiotics help the pregnancy last longer, but there have been limited studies about which combination works best. Currently, both azithromycin and erythromycin... Read More
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
06/03/2024
Locations: Eastern Viriginia Medical School, Norfolk, Virginia
Conditions: Premature Rupture of Membrane
Register for Updates
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
NCT05261139
Recruiting
The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID-19). The study medicine will be given to patients under 18 years of age with COVID-19 that are not hospitalized but are at risk for... Read More
Gender:
All
Ages:
Between 0 years and 17 years
Trial Updated:
06/03/2024
Locations: Childrens Hospital of The Kings Daughters, Norfolk, Virginia
Conditions: COVID-19
Register for Updates
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926
Recruiting
The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products (Faricimab and Port Delivery System with Ranibizumab) in approved retinal indications (neovascular age-related macular degeneration... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Wagner Macula and Retina Center, Norfolk, Virginia
Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Register for Updates
Outpatient Administration of Teclistamab for Multiple Myeloma
NCT05972135
Recruiting
This is a phase II study to evaluate the Outpatient Administration of Teclistamab in Multiple Myeloma Patients
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Virginia Oncology Associates, Norfolk, Virginia
Conditions: Multiple Myeloma
Register for Updates
Eliminating Monitor Overuse Trial (EMO Trial)
NCT05132322
Recruiting
The purpose of this study is to identify the optimal deimplementation strategies for an overused practice: continuous pulse oximetry monitoring of children hospitalized with bronchiolitis who are not receiving supplemental oxygen.
Gender:
All
Ages:
2 months and above
Trial Updated:
06/03/2024
Locations: Children's Hospital of The King's Daughters, Norfolk, Virginia
Conditions: Bronchiolitis Acute Viral
Register for Updates
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
NCT05313165
Recruiting
A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.
Gender:
All
Ages:
Between 18 years and 95 years
Trial Updated:
05/31/2024
Locations: Sentara Norfolk General Hospital, Norfolk, Virginia
Conditions: Critical Limb Ischemia, Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
NCT03958877
Recruiting
This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric participants with RRMS in Part 1. In Part 2, the study will evaluate the long-term safety of BIIB017 and further describe safety and the long-term multiple sclerosis (MS) outcomes after BIIB017 treatment in participants who completed the study treatment at Week 96 in Part... Read More
Gender:
All
Ages:
Between 10 years and 18 years
Trial Updated:
05/31/2024
Locations: Meridian Clinical Research, Norfolk, Virginia
Conditions: Multiple Sclerosis, Relapsing-Remitting
Register for Updates
Comparison of Two Pulmonary Embolism Treatments
NCT05684796
Recruiting
The primary objective of this trial is to evaluate the safety and efficacy of treatment with anticoagulation alone versus anticoagulation and mechanical aspiration thrombectomy with the Indigo Aspiration System for the treatment of intermediate-high risk acute pulmonary embolism (PE).
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/31/2024
Locations: Sentara Norfolk General Hospital, Norfolk, Virginia
Conditions: Pulmonary Embolism Acute
Register for Updates
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
NCT04743141
Recruiting
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolescents (≥ 6 to < 18 years of age).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
05/31/2024
Locations: Children's Hospital of The King's Daughters, Norfolk, Virginia +1 locations
Conditions: Acute Treatment of Migraine
Register for Updates
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
NCT06200207
Recruiting
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Sentara Clinical Research, Norfolk, Virginia
Conditions: Heart Failure, Systemic Inflammation
Register for Updates